Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-568
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationFY2026 Q4 (15-month irregular fiscal period)5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥803 million-50.0%
Operating profit¥-813 million
Ordinary income¥-830 million
Net income¥-816 million
Gross Profit Margin27.7%
Results for the three months of the current quarter
Net Sales
¥803 million
Gross profit
¥222 million
Operating profit (loss)
¥-813 million
Ordinary profit or loss
¥-830 million
Net income/loss before taxes
¥-812 million
Profit/loss after tax
¥-816 million
Full-year earnings forecast
After revision
Net Sales
¥1,044 million
Operating profit (loss)
¥-954 million
Ordinary profit or loss
¥-982 million
Net income (loss) for the current fiscal year
¥-986 million
Previous forecast
Net Sales
¥1,613 million
Operating profit (loss)
¥-853 million
Ordinary profit or loss
¥-864 million
Net income (loss) for the current fiscal year
¥-884 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales
12-month basis61.0%
15-month basis49.8%
Revenue on a contracted basis
12-month basis75.4%
15-month basis61.6%
Number of new contracts secured64.0%
Total number of contracts
12-month basis88.1%
15-month basis81.3%
Revenue by phase
Phase 1
12-month basis32.9%
15-month basis32.9%
Phase 2
12-month basis63.3%
15-month basis53.8%
Phase 3
12-month basis17.2%
15-month basis6.3%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revenue decline¥-568 million
- Decrease in cost of sales¥290 million
- SG&A cost reduction¥177 million
New initiatives
- Focus on the mining process business
- Deployment of new technology solutions, including low-concentration precious-metal recovery
- Development of mass-production equipment for tissue-engineered ligaments with CTBE
- Development with Corbex of microwave vacuum solvent distillation and recovery equipment
- Development aimed at in-house production of oscillators
Key KPIsA metric the company considers important as a management benchmark.
- Number of new contracts secured16 EngagementsYear on year against the same period last year16 compared with 24 in the previous full year
- Total number of contracts52 Engagements
- Number of contracts delivered43 Engagements
Medium-term management plan targets
FY2030 revenue¥10.0 billion
Phase 3 installations by FY20305 items
Revenue over the five years through FY2030¥13–14 billion in revenue over the five years through FY2030
Market Size / Share
Anterior cruciate ligament reconstruction surgery
JapanApproximately 19,000 procedures annually
United StatesApproximately 175,000 procedures annually
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | FY2026 Q4 (15-month irregular fiscal period) |
| Net Sales | ¥803 million (YoY -50.0%) |
| Operating profit | ¥-813 million |
| Ordinary income | ¥-830 million |
| Net income | ¥-816 million |
| Gross Profit Margin | 27.7% |
| Results for the three months of the current quarter | Net Sales ¥803 million / Gross profit ¥222 million / Operating profit (loss) ¥-813 million / Ordinary profit or loss ¥-830 million / Net income/loss before taxes ¥-812 million / Profit/loss after tax ¥-816 million |
| Full-year earnings forecast | After revision Net Sales ¥1,044 million / Operating profit (loss) ¥-954 million / Ordinary profit or loss ¥-982 million / Net income (loss) for the current fiscal year ¥-986 million / Previous forecast Net Sales ¥1,613 million / Operating profit (loss) ¥-853 million / Ordinary profit or loss ¥-864 million / Net income (loss) for the current fiscal year ¥-884 million |
| Progress against full-year forecast | Net Sales 12-month basis 61.0% / 15-month basis 49.8% / Revenue on a contracted basis 12-month basis 75.4% / 15-month basis 61.6% / Number of new contracts secured 64.0% / Total number of contracts 12-month basis 88.1% / 15-month basis 81.3% / Revenue by phase Phase 1 12-month basis 32.9% / 15-month basis 32.9% / Phase 2 12-month basis 63.3% / 15-month basis 53.8% / Phase 3 12-month basis 17.2% / 15-month basis 6.3% |
| Breakdown of Factors Affecting the Change | Factors Revenue decline / Amount ¥-568 million, Factors Decrease in cost of sales / Amount ¥290 million, Factors SG&A cost reduction / Amount ¥177 million |
| Key KPIs | Indicator name Number of new contracts secured / Value 16 Engagements / Year on year against the same period last year 16 compared with 24 in the previous full year, Indicator name Total number of contracts / Value 52 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of contracts delivered / Value 43 Engagements / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | FY2030 revenue ¥10.0 billion / Phase 3 installations by FY2030 5 items / Revenue over the five years through FY2030 ¥13–14 billion in revenue over the five years through FY2030 |
| Market Size / Share | Anterior cruciate ligament reconstruction surgery Japan Approximately 19,000 procedures annually / United States Approximately 175,000 procedures annually |
| New initiatives | Focus on the mining process business, Deployment of new technology solutions, including low-concentration precious-metal recovery, Development of mass-production equipment for tissue-engineered ligaments with CTBE, Development with Corbex of microwave vacuum solvent distillation and recovery equipment, Development aimed at in-house production of oscillators |
Items this document does not state (16)
Operating profit marginSelling, general and administrative expensesSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Delays in securing orders for multiple large-scale projects were the reason for the downward revision to the revenue forecast. The Company cited its high dependence on the chemical industry, the concentration of revenue in large-scale projects, oversupply in the chemical industry and customers' increasingly cautious investment decisions as background factors. It also deferred the procurement of raw materials and equipment associated with delayed projects and controlled hiring and other activities to limit the increase in the operating loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.